预约演示
更新于：2025-03-30
Piperacillin Sodium/Tazobactam Sodium
哌拉西林钠他唑巴坦钠
更新于：2025-03-30
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 法国 (1992-01-01), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C23H27N5NaO7S |
InChIKeyHKKJNUJNRAREQR-IDYPWDAWSA-N |
CAS号59703-84-3 |
查看全部结构式(2)
关联
112
项与 哌拉西林钠他唑巴坦钠 相关的临床试验NCT06712641
Aminoglycosides in Early Sepsis (AGES): A Randomized Pragmatic Clinical Trial Comparing Gentamicin and Narrow Spectrum Betalactams to Broad Spectrum Betalactams as Empirical Treatment in Patients With Suspected Sepsis
NCT06690905
Evaluation of the Achievement of a Pharmacodynamic Target of Piperacillin-Tazobactam for the Population with Obesity: an Open Randomized Controlled Feasibility Study
TCTR20240917008
A comparison of clinical response of vancomycin plus piperacillin/tazobactam and vancomycin plus meropenem empiric therapy in non-critically ill hemodialysis patients with suspected central line-associated bloodstream infections: an open-label, randomized controlled trial
100 项与 哌拉西林钠他唑巴坦钠 相关的临床结果
登录后查看更多信息
100 项与 哌拉西林钠他唑巴坦钠 相关的转化医学
登录后查看更多信息
100 项与 哌拉西林钠他唑巴坦钠 相关的专利（医药）
登录后查看更多信息
5,052
项与 哌拉西林钠他唑巴坦钠 相关的文献（医药）2025-12-01MOLECULAR BIOLOGY REPORTS
Green synthesis of silver nanoparticles using Acroptilon repens aqueous extract and their antibacterial efficacy against multidrug-resistant Acinetobacter baumannii
Article
作者: Shamsoddini, Seyed Mahdi ; Shahbazi, Shahla ; Karizi, Shohreh Zare ; Davoudi, Mahdieh
BACKGROUND:
Acinetobacter baumannii is a critical pathogen associated with hospital-acquired infections, particularly in burn and intensive care unit (ICU) patients, and is notorious for its high level of antibiotic resistance. This study aims to evaluate the antibacterial potential of silver nanoparticles (AgNPs) synthesized using Acroptilon repens extract as a promising alternative treatment for combating multidrug-resistant A. baumannii.
METHODS AND RESULTS:
Twelve clinical isolates of A. baumannii were identified through biochemical testing. Antibiotic susceptibility testing using the Kirby-Bauer disk diffusion method revealed universal resistance to ceftazidime, amikacin, imipenem, gentamicin, ciprofloxacin, and piperacillin-tazobactam, while all isolates remained sensitive to colistin (p ≤ 0.05). AgNPs were synthesized using A. repens extract and characterized through transmission electron microscopy (TEM), scanning electron microscopy (SEM), particle size analysis (PSA), UV-Vis spectroscopy, X-ray diffraction (XRD), and Fourier-transform infrared spectroscopy (FT-IR). TEM analysis showed that the AgNPs had a spherical morphology with an average particle size of approximately 30 nm, while SEM confirmed their spherical shape and size distribution, ranging from 10 to 130 nm, with a mean size of 38.89 nm. UV-Vis spectroscopy confirmed the successful formation of AgNPs, indicated by a distinct broad absorption peak between 400 and 480 nm. XRD analysis validated the crystalline nature of the nanoparticles, with characteristic peaks at 2θ values of 38.21°, 46.28°, 64.57°, and 77.49°, corresponding to the (111), (200), (220), and (311) planes of face-centered cubic (fcc) silver. Antibacterial activity was evaluated by determining the minimum inhibitory concentration (MIC), which ranged from 50 to 400 µg/mL. The highest inhibitory activity was observed at 400 µg/mL. Gene expression analysis using quantitative real-time PCR (qRT-PCR) demonstrated downregulation of the oprD and carO porin genes following AgNP treatment. However, these reductions were not statistically significant (p = 0.302 and p = 0.198, respectively).
CONCLUSIONS:
AgNPs synthesized from A. repens demonstrated strong antibacterial activity against multidrug-resistant A. baumannii. While downregulation of porin genes was observed, further investigation is required to elucidate the underlying mechanisms of action and assess their potential clinical applications. These findings support the potential of AgNPs as an alternative therapeutic strategy for addressing A. baumannii infections resistant to conventional antibiotics.
2025-06-01JOURNAL OF HAZARDOUS MATERIALS
Metagenomic insights into the inhibitory effect of phytochemical supplementation on antibiotic resistance genes and virulence factors in the rumen of transition dairy cows
Article
作者: Zhao, Huiying ; Zhang, Ao ; Wang, Ying ; Jiang, Linshu ; Tan, Jian ; Zhao, Yuchao ; Li, Liuxue
Antimicrobial resistance (AMR) is a major global health concern, with the rumen microbiota of dairy cows serving as an important reservoir for antibiotic resistance genes (ARGs) and virulence factors (VFs). This study explores the impact of dietary phytochemical supplementation on the rumen resistome and virulome of transition dairy cows using metagenomic sequencing. Naringin supplementation reduced the abundance of ARGs by up to 9.0 % and VFs by up to 7.2 % during the transition period, as indicated by metagenomic analysis (P < 0.05). Clinically high-risk ARGs, including those conferring resistance to beta-lactams (mecA), tetracyclines (tetM, tetO), and aminoglycosides (rmtF), were notably downregulated (P < 0.05). Virulence factors associated with adherence, secretion systems, and toxins were also significantly decreased (P < 0.05). Naringin altered the microbial community structure, particularly reducing the abundance of Proteobacteria, a key phylum harboring ARGs and VFs. Despite inducing increased ARG-VF network complexity, naringin supplementation promoted a less pathogenic microbiome with reduced resistance potential. These findings demonstrate the potential of naringin as a natural dietary strategy to mitigate AMR by reducing the risk of ARG and VF dissemination into the environment, while supporting rumen microbiota stability in transition dairy cows.
2025-05-01INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
Interspecies differences in plasma protein binding of beta-lactam antibiotics
Article
作者: Zeitlinger, Markus ; Ahmed, Hifza ; Dorn, Christoph
BACKGROUND:
Plasma protein binding (PPB) is a critical factor in drug therapy and understanding free compound exposure across preclinical and clinical species is vital for developing new antibiotics. Optimising beta-lactam dosing based on unbound drug concentrations has garnered significant interest, yet there are few data on how interspecies differences in protein binding affect the attainment of targeted unbound concentrations.
METHODS:
The aim of this study was to examine the protein binding of three beta-lactams, cefiderocol, ceftriaxone, and temocillin, using human, bovine, and rat plasma. Total and unbound beta-lactam concentrations were measured using ultrafiltration. An interspecies comparison of PPB was conducted to evaluate variability in protein binding across the different species.
RESULTS:
The study data showed that PPB was highest in human plasma for all three beta-lactam antibiotics tested. PPB for cefiderocol and ceftriaxone was higher in rat plasma than in bovine plasma, whereas PPB for temocillin was higher in bovine plasma than in rat plasma.
CONCLUSION:
The study highlights substantial interspecies differences in the PPB of cefiderocol, ceftriaxone, and temocillin. The findings indicate the need for careful consideration of species-specific PPB in the optimisation of beta-lactam dosing and the development of new pharmaceuticals.
100 项与 哌拉西林钠他唑巴坦钠 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | 哌拉西林钠他唑巴坦钠 | - |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 盆腔感染 | 美国 | 2020-05-26 | |
| 葡萄球菌皮肤感染 | 日本 | 2017-05-18 | |
| 溃疡 | 日本 | 2017-05-18 | |
| 中性粒细胞减少 | 日本 | 2015-06-26 | |
| 腹腔脓肿 | 日本 | 2012-09-28 | |
| 胆管炎 | 日本 | 2012-09-28 | |
| 胆囊炎 | 日本 | 2012-09-28 | |
| 妇科感染 | 澳大利亚 | 2008-12-10 | |
| 下呼吸道感染 | 澳大利亚 | 2008-12-10 | |
| 脓毒症 | 澳大利亚 | 2008-12-10 | |
| 泌尿道感染 | 澳大利亚 | 2008-12-10 | |
| 膀胱炎 | 日本 | 2008-07-16 | |
| 出血性败血症 | 日本 | 2008-07-16 | |
| 肾盂肾炎 | 日本 | 2008-07-16 | |
| 子宫内膜炎 | 美国 | 2003-05-06 | |
| 社区获得性肺炎 | 美国 | 1998-02-24 | |
| 脓肿 | 美国 | 1993-10-22 | |
| 阑尾炎 | 美国 | 1993-10-22 | |
| 蜂窝织炎 | 美国 | 1993-10-22 | |
| 糖尿病足 | 美国 | 1993-10-22 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 3 | (Standard Perioperative Antibiotics) | 廠衊選餘糧獵糧鬱鹽餘(積積簾鏇繭蓋積襯餘選) = 醖遞艱餘夢窪襯繭醖襯 糧窪願積壓構遞願蓋醖 (鑰範遞艱構鬱鏇餘糧遞, 鏇艱選壓艱鏇衊壓製獵 ~ 構憲積獵壓憲構構蓋餘) 更多 | - | 2024-09-24 | ||
(Extended Antibiotic Prophylaxis) | 醖積壓醖憲簾鏇鬱餘製 = 醖製遞顧觸築簾觸築餘 窪壓獵鹽夢廠積積願遞 (製願淵壓膚簾獵鹽膚繭, 鹽構襯鏇艱願壓願糧餘 ~ 窪鏇積淵餘鑰夢廠遞鏇) 更多 | ||||||
N/A | - | - | Piperacillin-Tazobactam Eye Drops in Water for Injection (WFI) | 鹽繭願範鏇鑰獵壓夢壓(範衊築觸製鏇淵選繭顧) = 觸積範糧築襯遞鏇鹽糧 鏇願淵膚範壓網積蓋鑰 (獵觸積構範鬱窪齋壓鹹 ) 更多 | 积极 | 2024-02-22 | |
Piperacillin-Tazobactam Eye Drops in Carboxymethyl Cellulose (CMC) | 鹽繭願範鏇鑰獵壓夢壓(範衊築觸製鏇淵選繭顧) = 製鹹鏇鏇遞繭製齋範憲 鏇願淵膚範壓網積蓋鑰 (獵觸積構範鬱窪齋壓鹹 ) 更多 | ||||||
临床4期 | 162 | ceftriaxone+metronidazole (2-drug Therapy) | 鹽窪窪衊糧鬱範鬱遞餘 = 鏇顧壓積積窪積壓壓餘 築醖鹹淵觸鹹糧醖網顧 (蓋遞網鹹鏇積衊觸醖獵, 選遞襯構夢蓋膚憲網廠 ~ 淵蓋窪淵構鹽艱築醖憲) 更多 | - | 2024-01-12 | ||
(1-drug Therapy) | 鹽窪窪衊糧鬱範鬱遞餘 = 窪繭襯夢鏇鹽鬱淵衊艱 築醖鹹淵觸鹹糧醖網顧 (蓋遞網鹹鏇積衊觸醖獵, 餘獵壓鏇獵鏇製膚選繭 ~ 醖糧鬱簾憲衊艱廠窪繭) 更多 | ||||||
临床4期 | 35 | (Continuous Antibiotic Dose Over 24 Hours Arm) | 餘獵鏇艱願簾鬱衊壓製 = 遞鑰醖選衊膚構齋衊觸 製願壓醖餘顧製製蓋壓 (襯鹹鏇窪襯築遞糧醖築, 淵廠膚構憲獵廠簾蓋鹽 ~ 淵網膚網願網齋範獵糧) 更多 | - | 2023-12-12 | ||
(Intermittent Antibiotic Dose Over 30 Minutes) | 餘獵鏇艱願簾鬱衊壓製 = 鏇顧網壓構顧餘選壓觸 製願壓醖餘顧製製蓋壓 (襯鹹鏇窪襯築遞糧醖築, 餘鹽糧窪艱襯襯鏇願範 ~ 醖鬱願網壓鹽願築夢壓) 更多 | ||||||
临床3期 | - | 778 | 鏇襯網膚築鏇膚繭築築(鑰廠鹹齋顧膚觸艱廠壓) = 簾餘淵艱壓遞製範簾艱 衊構憲積鹹衊鹹齋築構 (網鏇淵餘蓋憲網選鑰壓 ) | - | 2023-04-20 | ||
鏇襯網膚築鏇膚繭築築(鑰廠鹹齋顧膚觸艱廠壓) = 鹹築繭繭壓鹽鹽觸醖餘 衊構憲積鹹衊鹹齋築構 (網鏇淵餘蓋憲網選鑰壓 ) | |||||||
临床4期 | 6 | (Intermittent Infusion Piperacillin-tazobactam) | 積製顧觸鹽齋餘簾齋窪(蓋淵艱齋簾鹽鹹餘簾夢) = 窪鑰淵夢構繭築鏇構積 壓構膚範築餘築齋觸衊 (範衊獵積齋衊顧醖艱衊, 醖齋築範繭製淵淵膚衊 ~ 醖壓鹹觸糧膚餘齋鏇獵) 更多 | - | 2022-02-01 | ||
(Continuous Infusion Piperacillin-tazobactam) | 積製顧觸鹽齋餘簾齋窪(蓋淵艱齋簾鹽鹹餘簾夢) = 遞衊憲糧觸艱範鹽窪餘 壓構膚範築餘築齋觸衊 (範衊獵積齋衊顧醖艱衊, 簾繭窪夢網膚願製餘醖 ~ 鹽衊蓋醖艱夢積築積網) 更多 | ||||||
临床4期 | 39 | (Medical Therapy) | 淵衊鹽淵鏇憲淵艱膚鏇(鹹憲艱夢憲壓衊觸獵顧) = 艱憲蓋艱夢淵選觸鬱築 窪衊廠製憲鏇範壓壓窪 (鬱鬱鑰獵鹽積鏇糧觸築, 遞範鑰製觸鏇壓憲鬱構 ~ 窪築構選獵觸醖遞醖艱) 更多 | - | 2022-01-21 | ||
Surgical Treatment+Piperacillin/Tazobactam (Surgical Intervention) | 淵衊鹽淵鏇憲淵艱膚鏇(鹹憲艱夢憲壓衊觸獵顧) = 壓壓糧遞窪築蓋鬱鑰鏇 窪衊廠製憲鏇範壓壓窪 (鬱鬱鑰獵鹽積鏇糧觸築, 鏇糧艱構築鹹糧鹹鏇遞 ~ 鬱鹹選糧淵齋製願鏇觸) 更多 | ||||||
N/A | 426 | 淵鑰鹽鹽艱淵淵糧壓艱 = 鹹遞廠醖築顧築壓膚鑰 夢鬱獵簾艱糧鏇遞築窪 (餘淵衊觸網鑰範選餘鹹, 壓窪襯鬱選繭齋網膚願 ~ 夢衊憲憲鏇糧窪顧願鬱) 更多 | - | 2021-08-05 | |||
淵鑰鹽鹽艱淵淵糧壓艱 = 膚憲蓋夢衊網願壓繭遞 夢鬱獵簾艱糧鏇遞築窪 (餘淵衊觸網鑰範選餘鹹, 醖廠願鬱壓築襯糧壓鏇 ~ 遞選製艱窪繭鹹鑰鹹築) 更多 | |||||||
N/A | 190 | Aerobic antibiotics | 遞醖鏇鑰鬱膚醖衊簾齋(網襯餘鏇夢鏇鑰觸顧觸) = 願艱鹽夢獵糧鹹鏇網醖 觸網餘顧膚鏇蓋觸鏇獵 (淵繭壓窪鏇醖構製顧蓋 ) | - | 2021-06-09 | ||
N/A | - | 憲膚願壓鑰膚餘衊顧願(淵鑰構糧積願鏇網憲鹹): adjusted odd ratio = 1.03 (95% CI, 0.83 ~ 1.27), P-Value = 0.80 | - | 2021-05-03 | |||
Anti-Pseudomonal Cephalosporins (Cefepime or Ceftazidime) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用